Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis

References

• Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005;96:798–802.
   PubMedGoogle Scholar
• Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295–300.
   PubMed Web of Science ®Google Scholar
• Misop H, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 1999;5:87–92.
   Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315–30.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186–90, quiz 2435.
   PubMed Web of Science ®Google Scholar
• Urdaneta G, Solsona E, Palou J. Intravesical chemotherapy and BCG for the treatment of bladder cancer: evidence and opinion. Eur Urol Suppl 2008;7:542–7.
   Web of Science ®Google Scholar
• Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233–8.
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314–30.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). European Association of Urology; 2014. Available from http://www.uroweb.org/gls/pdf/05%20Non-muscle%20Invasive%20BC_TaT1_LR.pdf.
   Google Scholar
• Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, et al. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int 2012;110:967–72.
   PubMedGoogle Scholar
• Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008;179:101–5; discussion 105–6.
   PubMed Web of Science ®Google Scholar
• Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009;55:773–80.
   PubMed Web of Science ®Google Scholar
• Oude Elferink P, Witjes JA. Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. Ther Adv Urol 2014;6:25–33.
   PubMedGoogle Scholar
• Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62–7.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58–62.
   PubMed Web of Science ®Google Scholar
• O’Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112:1096–104.
   PubMed Web of Science ®Google Scholar
• Jichlinski P, Guillou L, Karlsen S. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer – a multicenter study. J Urol 2003;170:226–9.
   PubMed Web of Science ®Google Scholar
• Josefsen LB, Boyle RW. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2012;2:916–66.
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009;43:192–8.
   PubMed Web of Science ®Google Scholar
• Garfield SS, Gavaghan MB, Armstrong SO, Jones JS. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol 2013;20:6682–9.
   PubMedGoogle Scholar
• Marchetti A, Wang L, Magar R, Grossman HB, Lamm DL, Schellhammer PF, et al. Management of patients with bacilli Calmette–Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000;22:422–38.
   PubMed Web of Science ®Google Scholar
• Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294–303.
   PubMed Web of Science ®Google Scholar